China Medical System in-licensed China/Asian rights (excluding Japan) to a portfolio of oral cancer immunotherapy candidates developed by VAXIMM, a Swiss/German biotech. In return for the rights, CMS will participate in VAXIMM’s Series B round, plus make milestone payments and pay royalties. Specific details were not disclosed. VAXIMM’s candidates are based on an orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells.
Source: China Biotoday
